Myocardial Infarction clinical trials at UC Davis
1 research study open to eligible people
“Does high-dose influenza (“flu”) vaccine safely reduce heart or lung-related problems compared to the standard-dose flu vaccine?”
open to eligible people ages 18 years and up
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Sacramento, California and other locations